GlassScriptPhysician profile
David C Mendoza
NPI 1255374856
$2,330.20
in general payments reported to CMS, 2019-2025
27 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $735 · 2020: $512 · 2021: $133 · 2022: $55.10 · 2023: $286 · 2024: $473 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $894.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $938.74 | 2019-2024 | Xtandi |
| Sumitomo Pharma America, INC. | $169.89 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $167.26 | 2019-2025 | |
| Abbvie INC. | $134.10 | 2019-2024 | |
| Dornier Medtech America, INC | $130.53 | 2024 | Dornier Medtech |
| Boston Scientific Corporation | $116.51 | 2019-2024 | Rezum Generator |
| Neotract INC. | $63.97 | 2019-2020 | |
| Axonics, INC. | $62.67 | 2023-2024 | Axonics |
| Tolmar Pharmaceuticals, INC. | $53.43 | 2019 | |
| Myriad Genetic Laboratories, INC. | $51.84 | 2023-2024 | Prolaris |
| Merck Sharp & Dohme LLC | $47.43 | 2020-2024 | Lynparza, Welireg, Keytruda |
| Progenics Pharmaceuticals, INC. | $45.65 | 2023-2024 | Pylarify |
| Laborie Medical Technologies Corp. | $44.77 | 2025 | |
| Myovant Sciences INC. | $43.62 | 2021 | |
| Procept Biorobotics Corporation | $42.26 | 2024 | Aquabeam System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $35.10 | 2019 | |
| Tolmar, INC. | $28.90 | 2023 | |
| Ferring Pharmaceuticals INC. | $27.52 | 2024 | Adstiladrin |
| Depuy Synthes Sales INC. | $22.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.89 | 2025 | |
| Photocure INC | $16.11 | 2024 | Cysview |
| Bayer Healthcare Pharmaceuticals INC. | $15.47 | 2019 | |
| Travere Therapeutics, INC. | $14.84 | 2019 | |
| Coloplast Corp | $14.52 | 2025 | |
| Teleflex LLC | $13.81 | 2024 | Urolift |
| Urogen Pharma, INC. | $12.01 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$86.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mendoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.